Complex Monolithic Matrix for Chronotropic Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing controlled-release pharmaceutical formulations fail to achieve a gradual, constant colonic release of medicaments, leading to variability in release profiles and inadequate distribution in the gastrointestinal tract, resulting in suboptimal treatment and increased adverse effects.
Innovation Solution
A solid oral controlled-release composition featuring a core with a complex monolithic matrix of hydroxypropyl methylcellulose with varying viscosities, methacrylic polymers, and shellac, combined with an outer gastroresistant coating of ethylcellulose, which modulates the release of active ingredients based on pH and transit times in the gastrointestinal tract.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If single-component systems are used for controlled-release formulations, then the formulation is simple to manufacture, but the release precision is low and variability is high
Solution Approach 1:
The patent uses composite polymer systems combining hydroxypropyl methylcellulose (HPMC) with varying viscosities (low/medium viscosity HPMC 5 Premium and medium/high viscosity HPMC K100M) together with methacrylic polymers (Eudragit L100/55 and Eudragit S100) and shellac. This multi-component composite approach creates a complex matrix that achieves precise and reproducible drug release profiles with low variability, resolving the contradiction between manufacturing simplicity and release precision by using a systematically designed composite material system.
2Reliability
If gastroresistant and lag-time forms are used, then the medicament is protected in the stomach, but erratic release occurs in the distal ileum and initial colon
Solution Approach 1:
The patent applies local quality by creating a complex matrix with spatially differentiated polymer properties. The combination of HPMC with different viscosities provides zones of varying gel formation and drug release rates within the matrix, ensuring homogeneous distribution and controlled release throughout the gastrointestinal tract including the distal ileum and colon, while maintaining gastric protection through the gastroresistant coating.
3Device complexity
If single viscosity HPMC is used in the matrix, then the formulation is simple, but the release profile shows high variability
Solution Approach 1:
The patent systematically changes the viscosity parameter of HPMC by combining low/medium viscosity HPMC 5 Premium (viscosity 5-1000 mPa·s) with medium/high viscosity HPMC K100M (viscosity 1000-10000 mPa·s). This parameter variation creates a complex matrix with multiple gel formation rates and drug diffusion pathways, achieving reproducible release profiles with low variability while accepting increased formulation complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach ensures a homogeneous, reproducible release profile with low variability, maintaining the active ingredient's bioavailability for up to 24 hours, optimizing therapeutic efficacy and reducing side effects by tailoring the release to specific sites and times within the gastrointestinal tract.
Implementation Method 1
Time-specific and site-specific release is achieved by exploiting variations in pH and the different transit times of the medicaments in the gastrointestinal apparatus
Implementation Method 2
solid oral controlled-release pharmaceutical compositions comprising a core consisting of a complex monolithic matrix
Implementation Method 3
an outer coating of said core consisting of a layer comprising ethylcellulose, or of a gastroresistant layer or of a layer comprising ethylcellulose coated in turn with gastroresistant polymers
Data Source
AI summary
The present invention relates to solid oral controlled-release pharmaceutical compositions comprising a core consisting of a complex monolithic matrix comprising at least one low/medium viscosity hydroxypropyl methylcellulose, at least one medium/high viscosity hydroxypropyl methylcellulose, one or more methacrylic polymers or copolymers and/or cellulose acetate phthalate and/or hydroxypropyl methylcellulose acetate succinate or shellac, and an outer coating of said core consisting of a layer comprising ethylcellulose, or of a gastroresistant layer or of a layer comprising ethylcellulose coated in turn with gastroresistant polymers.